Cover Page - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Feb. 27, 2026 |
Jun. 30, 2025 |
|
| Document Information [Line Items] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity File Number | 001-42179 | ||
| Entity Registrant Name | Artiva Biotherapeutics, Inc. | ||
| Entity Central Index Key | 0001817241 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 83-3614316 | ||
| Entity Address, Address Line One | 5505 Morehouse Drive | ||
| Entity Address, Address Line Two | Suite 100 | ||
| Entity Address, City or Town | San Diego | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 92121 | ||
| City Area Code | 858 | ||
| Local Phone Number | 267-4467 | ||
| Title of 12(b) Security | Common Stock, par value $0.0001 per share | ||
| Trading Symbol | ARTV | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | false | ||
| Entity Shell Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Documents Incorporated by Reference [Text Block] | DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive proxy statement relating to its 2026 annual meeting of shareholders (the Proxy Statement) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates. |
||
| Entity Public Float | $ 15.0 | ||
| Entity Common Stock, Shares Outstanding | 24,716,672 | ||
| Auditor Name | KPMG LLP | ||
| Auditor Firm ID | 185 | ||
| Auditor Location | San Diego, California | ||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements We have audited the accompanying balance sheets of Artiva Biotherapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. |